Quoin Pharmaceuticals Ltd
QNRX8.570USD
-1.080-11.19%
Close 11/06, 16:00（ET）Quotes delayed by 15 min
176.42MMarket Cap
LossP/E TTM
More Details of Quoin Pharmaceuticals Ltd Company
Quoin Pharmaceuticals Ltd, former Cellect Biotechnology Ltd, is an Israel-based specialty pharmaceutical company, focused on developing and commercializing therapeutic products that treat rare and orphan diseases. The Company’s first lead product is QRX003, a once daily, topical lotion comprised of a broad-spectrum serine protease inhibitor, formulated with the proprietary Invisicare technology, to treat Netherton Syndrome. The product going to be developed for other rare dermatological diseases including Peeling Skin Syndrome, SAM Syndrome, and Palmoplantar Keratoderma. Quoin is also developing QRX004 as a potential treatment for Dystrophic Epidermolysis Bullosa, and QRX006 as a potential therapy for an, as of yet, undisclosed rare skin disease.
Quoin Pharmaceuticals Ltd Info
Ticker SymbolQNRX
Company nameQuoin Pharmaceuticals Ltd
IPO dateNov 01, 1989
CEODr. Michael Myers, Ph.D.
Number of employees3
Security typeDepository Receipt
Fiscal year-endNov 01
Address23 Hata'as Street
CityKFAR SABA
Stock exchangeNASDAQ Capital Market Consolidated
CountryIsrael
Postal code44425
Phone97299741444
Websitehttps://quoinpharma.com/
Ticker SymbolQNRX
IPO dateNov 01, 1989
CEODr. Michael Myers, Ph.D.
Company Executives of Quoin Pharmaceuticals Ltd
Name
Name/Position
Position
Shareholding
Change
Dr. Michael Myers, Ph.D.
Dr. Michael Myers, Ph.D.
Chairman of the Board, Chief Executive Officer
Chairman of the Board, Chief Executive Officer
17.22K
--
Ms. Sally Lawlor
Ms. Sally Lawlor
Chief Financial Officer
Chief Financial Officer
440.00
--
Dr. Amos Ofer
Dr. Amos Ofer
Chief Operating Officer, Vice President
Chief Operating Officer, Vice President
--
--
Dr. Amotz Nehushtan
Dr. Amotz Nehushtan
Vice President - Research & Development & Product Development
Vice President - Research & Development & Product Development
--
--
Mr. David L. Braun
Mr. David L. Braun
Independent Director
Independent Director
--
--
Ms. Ronit Biran
Ms. Ronit Biran
Independent Director
Independent Director
--
--
Mr. Jonathan Burgin, CPA
Mr. Jonathan Burgin, CPA
Independent External Director
Independent External Director
--
--
Mr. Jonathan Burgin, CPA
Mr. Jonathan Burgin, CPA
Independent External Director
Independent External Director
--
--
Mr. Yali Sheffi
Mr. Yali Sheffi
Independent External Director
Independent External Director
--
--
Mr. Guy Sapir
Mr. Guy Sapir
Internal Auditor
Internal Auditor
--
--
View more
Name
Name/Position
Position
Shareholding
Change
Dr. Michael Myers, Ph.D.
Dr. Michael Myers, Ph.D.
Chairman of the Board, Chief Executive Officer
Chairman of the Board, Chief Executive Officer
17.22K
--
Ms. Sally Lawlor
Ms. Sally Lawlor
Chief Financial Officer
Chief Financial Officer
440.00
--
Dr. Amos Ofer
Dr. Amos Ofer
Chief Operating Officer, Vice President
Chief Operating Officer, Vice President
--
--
Dr. Amotz Nehushtan
Dr. Amotz Nehushtan
Vice President - Research & Development & Product Development
Vice President - Research & Development & Product Development
--
--
Mr. David L. Braun
Mr. David L. Braun
Independent Director
Independent Director
--
--
Ms. Ronit Biran
Ms. Ronit Biran
Independent Director
Independent Director
--
--
Revenue Breakdown
No Data
No Data
By Business
By Region
No Data
Shareholding Stats
Updated: Sun, Sep 14
Updated: Sun, Sep 14
Shareholders
Shareholder Types
Shareholders
Shareholders
Proportion
Myers (Michael)
2.85%
Carter (Denise P)
2.85%
Langer (Dennis H)
2.51%
Dunn (Gordon)
0.72%
Culverwell (Anthony James)
0.47%
Other
90.59%
Shareholders
Shareholders
Proportion
Myers (Michael)
2.85%
Carter (Denise P)
2.85%
Langer (Dennis H)
2.51%
Dunn (Gordon)
0.72%
Culverwell (Anthony James)
0.47%
Other
90.59%
Shareholder Types
Shareholders
Proportion
Individual Investor
9.48%
Investment Advisor
0.35%
Investment Advisor/Hedge Fund
0.05%
Research Firm
0.03%
Other
90.09%
Institutional Shareholding
Updated: Wed, Oct 1
Updated: Wed, Oct 1
Reporting Period
No. of institutions
Shares Held
Proportion
Change
2025Q3
28
2.58K
0.43%
-52.65K
2025Q2
34
51.05K
8.68%
-35.06K
2025Q1
35
78.22K
9.34%
-7.90K
2024Q4
33
2.93M
35.77%
+2.56M
2024Q3
29
288.95K
5.54%
-93.09K
2024Q2
30
301.96K
12.37%
-13.30K
2024Q1
28
276.13K
11.96%
+132.88K
2023Q4
28
104.03K
10.54%
-33.36K
2023Q3
27
83.72K
8.48%
+6.49K
2023Q2
28
91.62K
18.66%
+37.20K
View more
Shareholder Activity
Name
Shares Held
Proportion
Change
Chg %
Date
Myers (Michael)
17.22K
0.08%
--
--
Jul 16, 2025
Carter (Denise P)
17.22K
0.08%
-1.00
-0.01%
Jul 16, 2025
Langer (Dennis H)
1.00
0%
-1.00
-50.00%
Jul 16, 2025
Dunn (Gordon)
4.32K
0.02%
--
--
Jul 16, 2025
Culverwell (Anthony James)
2.87K
0.01%
--
--
Jul 16, 2025
Rhumbline Advisers Ltd. Partnership
1.24K
0.01%
+49.00
+4.11%
Jun 30, 2025
Raymond James Financial Services Advisors, Inc.
717.00
0%
-1.00
-0.14%
Jun 30, 2025
Lawlor (Sally Bridget)
440.00
0%
+440.00
--
Aug 18, 2025
GAMMA Investing LLC
278.00
0%
+38.00
+15.83%
Sep 30, 2025
Morgan Stanley & Co. LLC
206.00
0%
+193.00
+1484.62%
Jun 30, 2025
View more
Related ETFs
Name
Proportion
No Data
Dividend
A total of
0.00
USD has been distributed in dividends over the past 5 years.
Date
Dividend
Record Date
Payment Date
Ex-dividend Date
No Data
Stock Split
Date
Type
Ratio
Mar 26, 2025
Merger
20→1
Jun 28, 2023
Merger
12→1
Jun 28, 2023
Merger
12→1
Jun 28, 2023
Merger
12→1
Jun 28, 2023
Merger
12→1
Jul 29, 2022
Merger
12.5→1
Date
Type
Ratio
Mar 26, 2025
Merger
20→1
Jun 28, 2023
Merger
12→1
Jun 28, 2023
Merger
12→1
Jun 28, 2023
Merger
12→1
Jun 28, 2023
Merger
12→1
Jul 29, 2022
Merger
12.5→1
Jul 29, 2022
Merger
12.5→1
Jul 29, 2022
Merger
12.5→1
Jul 29, 2022
Merger
12.5→1
Sep 23, 2021
Merger
4→1
View more
